Back to search

France· FR:69211156

FASTURTEC 1,5 mg/ml, poudre et solvant pour solution à diluer pour perfusion

A rasburicase product containing rasburicase, registered in France by SANOFI WINTHROP INDUSTRIE. The same ATC class is registered in 13 of our 19 countries.

ATC V03AF07

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedFASTURTEC 1,5 mg/ml, poudre et solvan…ATCV03AF07REGISTER NO.FR:69211156PACKS LISTED2CHECKEDSeptember 12, 2026

Where it is registered

Rasburicase is registered in 13 of 19 countries.

Countries holding a registration under ATC V03AF07 (rasburicase), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 8 of them publish a price we can compare per daily dose

Rasburicase · ATC V03AF07

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
RASBURICASE
Manufacturer
SANOFI WINTHROP INDUSTRIE
Country
France (FR)
ATC code
V03AF07
ATC class
Rasburicase
Defined daily dose
14 mg, P
Reimbursed
No
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 2

  • cip13
    3400956213917
    3 flacon(s) en verre - 3 ampoule(s) en verre de 1 ml
  • cip13
    3400956341238
    1 flacon(s) en verre - 1 ampoule(s) en verre de 5 ml

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

25 interactions on record for rasburicase.

Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Rasburicase · interactions on record

25 records

  • 1 severe
  • 24 moderate

Most severe, free to view

  • PrilocaineN01BB04severe
  • LidocainA01AE01moderate
  • TetracainA01AE02moderate
  • LidocaineC05AD01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ec995791-d49c-45db-a6d7-33be74460d5a
GET /v1/drugs/ec995791-d49c-45db-a6d7-33be74460d5a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "69211156",
  "date_amm": "2001-02-23",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/00/170",
  "substance": "RASBURICASE",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "poudre et  solvant pour solution à diluer pour perfusion",
  "voies_administration": "intraveineuse",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}

See everything about rasburicase.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.